Boc-3-(2-噻吩基)-L-丙氨酸 | 56675-37-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-3-(2-噻吩基)-L-丙氨酸
• 中文别名: N-叔丁氧羰基-3-(2-噻吩基)-L-丙氨酸；Boc-L-3-（2-噻吩基）-丙氨酸；丁氧羰基-3-(2-噻唑基)-L-苯丙酸；丁氧羰基-Β-(2-噻吩基)-丙氨酸羟基；BOC-L-2-噻吩基丙氨酸；(S)-N-BOC-2-噻吩基丙氨酸；N-BOC-3-(2-噻吩基)-L-丙氨酸；BOC-L-3-(2-噻吩基)-丙氨酸
• 英文名称: (S)-2-tert-butoxycarbonylamino-3-thiophen-2-yl-propionic acid
• 英文别名: N-(tert-butoxycarbonyl)-3-(thien-2-yl)-L-alanine；(2S)-2-[(tert-butoxycarbonyl)amino]-3-(thiophen-2-yl)propanoic acid；(S)-2-((tert-butoxycarbonyl)amino)-3-(thiophen-2-yl)propanoic acid；N-(tert-butoxycarbonyl)-3-thiophen-2-yl-L-alanine；boc-β-(2-thienyl)-alanine；Boc(2-thienyl)alanine；(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-thiophen-2-ylpropanoic acid
• CAS: 56675-37-7
• 化学式: C₁₂H₁₇NO₄S
• mdl: MFCD00062051
• 分子量: 271.337
• InChiKey: OJLISTAWQHSIHL-VIFPVBQESA-N

物化性质

• 熔点：
  71-76 °C
• 比旋光度：
  11 º (c=1% in MeOH)
• 密度：
  1.2791 (rough estimate)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，且目前没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	(S)-N-BOC-2-Thienylalanine, 95%, (98% E.E.) Material Safety Data Sheet
Synonym:	N-tert-Butoxycarbonyl-2-Thienyl-L-Alanine.
CAS:	56675-37-7

Section 1 - Chemical Product MSDS Name: (S)-N-BOC-2-Thienylalanine, 95%, (98% E.E.) Material Safety Data Sheet
Synonym: N-tert-Butoxycarbonyl-2-Thienyl-L-Alanine.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
56675-37-7	(S)-N-BOC-2-Thienylalanine	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 56675-37-7: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 71-76 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H17NO4S
Molecular Weight: 271.33

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 56675-37-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-N-BOC-2-Thienylalanine - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 56675-37-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 56675-37-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 56675-37-7 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 1/16/2002 Revision #2 Date: 10/05/2004 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Boc-3-(2-噻吩基)-L-丙氨酸 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-[1,2]Dithiolan-3-yl-pentanoic acid [(S)-1-((S)-2-ethylcarbamoyl-2-hydroxy-1-thiophen-2-ylmethyl-ethylcarbamoyl)-2-methyl-propyl]-amide
  参考文献：
  名称：

  Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

  摘要：

  Dipeptide-derived alpha-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.064
• 作为产物：
  描述：

  3-(2-噻吩基)-DL-丙氨酸 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 Boc-3-(2-噻吩基)-L-丙氨酸
  参考文献：
  名称：

  Lipkowski, Andrzej W.; Flouret, George, Polish Journal of Chemistry, 1980, vol. 54, # 11/12, p. 2225 - 2228

  摘要：

  DOI：

文献信息

• Interaction of Papain-like Cysteine Proteases with Dipeptide-Derived Nitriles
  作者：Reik Löser、Klaus Schilling、Elke Dimmig、Michael Gütschow

  DOI：10.1021/jm050686b

  日期：2005.12.1

  were introduced, and systematic fluorine, bromine, and phenyl scans for phenylalanine in the P2 position were performed. Moreover, the N-terminal protection was varied. Kinetic investigations were carried out with cathepsin L, S, and K as well as papain. Changes in the backbone structure of the parent N-(tert-butoxycarbonyl)-phenylalanyl-glycine-nitrile (16), such as the introduction of an R-configured

  制备一系列44个在P2位具有各种氨基酸和在P1位具有甘氨酸的二肽腈，并将其评估为半胱氨酸蛋白酶的抑制剂。关于P2-S2相互作用对酶抑制剂复合物形成的重要贡献，重点是将结构多样性引入P2侧链。引入了非蛋白氨基酸，并进行了系统的氟，溴和苯基扫描，以检测P2位置的苯丙氨酸。而且，N-末端保护是多种多样的。使用组织蛋白酶L，S和K以及木瓜蛋白酶进行动力学研究。母体N-（叔丁氧羰基）-苯丙氨酰基-甘氨酸-腈的骨架结构变化（16），例如将R构型的氨基酸或氮杂氨基酸引入P2以及P1氮的甲基化，会导致亲和力的急剧下降。示例性地，16的氰基被醛或甲基酮官能团取代。关于靶酶的底物特异性，讨论了构效关系。
• Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors
  作者：Xun Ji、Mingbo Su、Jiang Wang、Guanghui Deng、Sisi Deng、Zeng Li、Chunlan Tang、Jingya Li、Jia Li、Linxiang Zhao、Hualiang Jiang、Hong Liu

  DOI：10.1016/j.ejmech.2014.01.021

  日期：2014.3

  A series of novel hetero-aromatic moieties substituted α-amino pyrrole-2-carbonitrile derivatives was designed and synthesized based on structure–activity relationships (SARs) of pyrrole-2-carbonitrile inhibitors. All compounds demonstrated good dipeptidyl peptidase IV (DPP4) inhibitory activities (IC50 = 0.004–113.6 μM). Moreover, compounds 6h (IC50 = 0.004 μM) and 6n (IC50 = 0.01 μM) showed excellent

  基于吡咯-2-腈抑制剂的构效关系（SARs），设计合成了一系列新颖的杂芳族取代α-氨基吡咯-2-腈衍生物。所有化合物均表现出良好的二肽基肽酶IV（DPP4）抑制活性（IC 50  = 0.004–113.6μM）。此外，化合物6h（IC 50  = 0.004μM）和化合物6n（IC 50  = 0.01μM）对DPP4表现出优异的抑制活性，选择性好（化合物6h，选择比：DPP8 / DPP4 = 450.0； DPP9 / DPP4 = 375.0；化合物6n，选择性比率：DPP8 / DPP4 = 470.0；DPP9 / DPP4 = 750.0），并且在ICR小鼠的口服葡萄糖耐量试验中有良好的疗效。此外，化合物6h和6n表现出中等PK性能（化合物6h，F％＝ 37.8％，t 1/2  ＝ 1.45h；化合物6n，F％＝ 16.8％，t 1/2  ＝ 3.64h）。
• Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity
  作者：BinQing Wei、Janet Gunzner-Toste、Hui Yao、Tao Wang、Jing Wang、Zijin Xu、Jinhua Chen、John Wai、Jim Nonomiya、Siao Ping Tsai、Josefa Chuh、Katherine R. Kozak、Yichin Liu、Shang-Fan Yu、Jeff Lau、Guangmin Li、Gail D. Phillips、Doug Leipold、Amrita Kamath、Dian Su、Keyang Xu、Charles Eigenbrot、Stefan Steinbacher、Rachana Ohri、Helga Raab、Leanna R. Staben、Guiling Zhao、John A. Flygare、Thomas H. Pillow、Vishal Verma、Luke A. Masterson、Philip W. Howard、Brian Safina

  DOI：10.1021/acs.jmedchem.7b01430

  日期：2018.2.8

  Antibody–drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker

  抗体-药物偶联物（ADC）已成为肿瘤学的重要治疗手段，其中三种已获得FDA批准，另外60多项已在临床试验中获得批准。尽管取得了进步，但仍需要改善ADC治疗指数。被溶酶体蛋白酶裂解的基于肽的ADC接头在血清中显示出足够的稳定性，并在靶细胞中有效释放有效负载。如果该接头可以被肿瘤特异性蛋白酶优先水解，则安全系数可能会提高。但是，基于肽的接头的使用限制了我们调节蛋白酶特异性的能力。在这里，我们报告新型非肽类ADC接头的结构指导发现。我们表明，含有环丁烷-1,1-二羧酸的连接子主要被组织蛋白酶B水解，而缬氨酸-瓜氨酸二肽连接子则不被水解。带有非肽接头的ADC在体内与具有二肽接头的ADC一样有效和稳定。我们的结果有力地支持了拟肽连接子的应用，并为改善ADC的选择性提供了新的机会。
• C–H Alkenylation of Heteroarenes: Mechanism, Rate, and Selectivity Changes Enabled by Thioether Ligands
  作者：Bradley J. Gorsline、Long Wang、Peng Ren、Brad P. Carrow

  DOI：10.1021/jacs.7b03887

  日期：2017.7.19

  catalytic intermediate in these reactions may also account for unusual catalyst-controlled site selectivity wherein C–H alkenylation of five-atom heteroarenes can occur under electronic control with thioether ligands even when this necessarily involves reaction at a more hindered C–H bond. The thioether effect also enables short reaction times under mild conditions for many O-, S-, and N-heteroarenes (55 examples)

  已确定硫醚辅助配体可以大大促进O-，S-和N的C–H烯基化-杂芳烃。动力学数据表明，硫醚-Pd催化的反应比经典的无配体系统快800倍之多。此外，机理研究表明，C–H键的裂解是限制周转的步骤，硫醚配位时的速率加速与该关键步骤从中性途径向阳离子途径的变化相关。在这些反应中形成阳离子型，低配位的催化中间体也可能说明了催化剂控制位点的异常，其中五原子杂芳烃的CH链烯基化可以在硫代配体的电子控制下发生，即使这必然涉及在更阻碍了CH键的键合。硫醚效应还使得许多O-，S-和N-杂芳烃（55个实例），包括晚期药物衍生化的实例。
• SUBSTITUTED HYDANTOINS
  申请人：Chen Shaoqing

  公开号：US20090048452A1

  公开（公告）日：2009-02-19

  This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components of the MAP kinase signal transduction pathway and as such the compounds will have anti-hyperproliferative cellular activity.

  这项发明涉及以下式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3、R4、R5和R6在本申请中有描述。这些化合物抑制MEK 1和MEK2酶，这是MAP激酶信号转导途径的组成部分，因此这些化合物将具有抗高增殖细胞活性。